3. Response to ramucirumab plus paclitaxel according to gMDSC kinetics.

Disease status	n (%)		P
	gMDSC increase <44%	gMDSC increase ≥44%
gMDSC, granulocytic myeloid-derived suppressor cell; PR, partial response; SD, stable disease; PD, progressive disease; CR, complete remission.
Measurable disease			0.033
PR+SD	24 (100)	8 (66.7)
PD	0 (0)	4 (33.3)
Non-measurable disease			0.009
Non-CR/non-PD	18 (90.0)	4 (50.0)
PD	2 (10.0)	4 (50.0)